Search
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. … It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name
Orlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalObesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. … It was approved by the FDA for use in combination with a reduced-calorie diet in 1999.
Products: ORLISTAT MK 120 MG CAPSULASLetrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigationalLetrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. … [A190546] Letrozole was granted FDA approval on 25 July 1997.[L11623]
Mixtures: Kisqali Femara Co-pack, Kisqali Femara Co-packProducts: Co LetrozoleRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigational[L38814] The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawn[A229363] Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.
Primidone
go.drugbank.com/drugs/DB00794ApprovedVet approved[L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112] … Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.
Beeswax
go.drugbank.com/drugs/DB11600ApprovedBeeswax is used as a stiffening agent in ointments and creams, and enables water to be incorporated to produce water-in-oil emulsions.
Gepirone
go.drugbank.com/drugs/DB12184Approved[A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder. … It was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeStrontium ranelate
go.drugbank.com/drugs/DB09267ApprovedWithdrawnAvailable for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … Furthermore, various clinical studies demonstrate the ability of strontium ranelate to improve and strengthen intrinsic bone tissue quality and microarchitecture in osteoporosis by way of a number of cellular